(HTEC) Robo Global Healthcare - Ratings and Ratios
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US3015057231
HTEC: Medical Devices, Healthcare Software, AI Technology, Telemedicine Services
The Robo Global Healthcare Technology and Innovation ETF (HTEC) is an exchange-traded fund that focuses on investing in companies that derive a significant portion of their revenue from healthcare technology and have the potential for growth through innovation and market adoption.
The funds investment strategy is centered around tracking an index that comprises companies in the healthcare technology space, with a minimum of 80% of its total assets allocated to securities of the index or depositary receipts representing these securities. This concentrated approach indicates that the fund is non-diversified, which can result in higher volatility but also potentially higher returns if the selected companies perform well.
Given the current technical indicators, with the last price at $27.59, the fund is trading above its 20-day and 50-day simple moving averages (SMA20 and SMA50) of $27.00 and $26.88, respectively, indicating a short-term bullish trend. However, it is still below its 200-day simple moving average (SMA200) of $28.73, suggesting that the long-term trend is bearish. The Average True Range (ATR) of 0.65, representing a 2.34% daily volatility, indicates moderate price movements.
From a fundamental perspective, the funds Assets Under Management (AUM) stand at $44.08 million, which is a relatively modest size. This could be both a positive and a negative factor; on one hand, it might limit the funds ability to invest in a wide range of securities, but on the other hand, it could allow for more agile investment decisions.
Forecasting future performance based on the available technical and fundamental data, it is plausible that HTEC could experience a bullish trend if it breaks above its SMA200. A sustained move above $28.73 could attract more investors, potentially driving the price up towards its 52-week high of $31.35. Conversely, failure to break through this resistance level, combined with the current bearish long-term trend, might result in the price retreating towards its 52-week low of $24.16. Therefore, a key level to watch is $28.73, as a breakout above this could signal a significant shift in the funds price action.
Additional Sources for HTEC ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
HTEC ETF Overview
Market Cap in USD | 44m |
Category | Health |
TER | 0.68% |
IPO / Inception | 2019-06-24 |
HTEC ETF Ratings
Growth Rating | -30.9 |
Fundamental | - |
Dividend Rating | 1.0 |
Rel. Strength | -8.74 |
Analysts | - |
Fair Price Momentum | 24.16 USD |
Fair Price DCF | - |
HTEC Dividends
Currently no dividends paidHTEC Growth Ratios
Growth Correlation 3m | 7.6% |
Growth Correlation 12m | -23% |
Growth Correlation 5y | -76.5% |
CAGR 5y | -1.39% |
CAGR/Max DD 5y | -0.02 |
Sharpe Ratio 12m | -0.20 |
Alpha | -10.76 |
Beta | 0.829 |
Volatility | 25.28% |
Current Volume | 8.1k |
Average Volume 20d | 3.5k |
As of June 17, 2025, the stock is trading at USD 27.57 with a total of 8,074 shares traded.
Over the past week, the price has changed by -1.12%, over one month by +2.20%, over three months by -2.58% and over the past year by +0.85%.
Probably not. Based on ValueRay´s Analyses, Robo Global Healthcare (NYSE ARCA:HTEC) is currently (June 2025) not a good stock to buy. It has a ValueRay Growth Rating of -30.94 and therefor a somwhat technical negative rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HTEC is around 24.16 USD . This means that HTEC is currently overvalued and has a potential downside of -12.37%.
Robo Global Healthcare has no consensus analysts rating.
According to our own proprietary Forecast Model, HTEC Robo Global Healthcare will be worth about 27.3 in June 2026. The stock is currently trading at 27.57. This means that the stock has a potential downside of -0.87%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 27.3 | -0.9% |